Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | TGAN | Common Stock | Purchase | $5.73M | +1.74M | +7.66% | $3.30 | 24.4M | Jul 21, 2023 | See footnotes | F1, F2, F3 |
Id | Content |
---|---|
F1 | Shares of common stock, $0.0001 par value (the "Common Stock") of Transphorm, Inc. (the "Issuer") issued pursuant to a pro rata subscription rights offering (the "Rights Offering"), which entitled all holders of Common Stock to purchase 0.07655623 of a share of the Issuer's Common Stock, for every share of Common Stock held at a subscription price of $3.30 per whole share. The Rights Offering closed on July 21, 2023. |
F2 | The securities reported herein are held by KKR Phorm Investors L.P. KKR Phorm Investors GP LLC is the general partner of KKR Phorm Investors L.P., KKR Group Partnership L.P. is the sole member of KKR Phorm Investors GP LLC, KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P., KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp., KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc., KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP. |
F3 | Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein. |